Moderna announces its covid-19 vaccine phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint

Two 25 Μg doses of mrna-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mrna-1273 was generally well tolerated in this age group although not a primary endpoint, statistically significant vaccine efficacy was observed during the omicron wave that was consistent with the lower two-dose effectiveness against omicron seen in adults moderna is moving forward with global regulatory submissions for mrna-1273 for primary vaccination of children 6 months to under 6 years of age additionally, moderna has initiated a submission to the fda for emergency use authorization of mrna-1273 in children 6 to under 12 years of age; mrna-1273 is approved for use in this age group in europe, canada and australia cambridge, ma / accesswire / march 23, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced positive interim data from the phase 2/3 kidcove study of the moderna covid-19 vaccine (mrna-1273) in children 6 months to under 2 years and 2 years to under 6 years of age. this interim analysis showed a robust neutralizing antibody response in both age groups after a 25 Μg two-dose primary series of mrna-1273 along with a favorable safety profile.
MRNA Ratings Summary
MRNA Quant Ranking